Ken Griffin
ADIL

Ken Griffin’s Adial Pharmaceuticals ADIL Stock Holding History

Ken Griffin’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34
Closed -$28K – 12498
2022
Q2 		$28K Buy
+34
New +$30.8K ﹤0.01% 12254
2022
Q1 		– Sell
-62
Closed -$105K – 13463
2021
Q4 		$105K Buy
+62
New +$122K ﹤0.01% 12668

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
MCM
Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RWML
RAFFA WEALTH MANAGEMENT, LLC Washington, District of Columbia $793M AUM 13.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Ken Griffin's ADIL Position: Q1 2026 in Review

Ken Griffin sold out of Adial Pharmaceuticals (ADIL) in Q1 2026, closing a stake of 8,785 shares — an estimated $48.3K sold.

Ken Griffin first reported a position in ADIL in Q1 2019 and held it in 10 quarters. The position peaked at $180K in Q1 2021. 15 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Ken Griffin reported no remaining Adial Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 8,785 Adial Pharmaceuticals shares in Q1 2026, an estimated $48.3K.
  • Ken Griffin first reported a position in Adial Pharmaceuticals in Q1 2019 and held it in 10 quarters.
  • Ken Griffin's Adial Pharmaceuticals position peaked at $180K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.